Willow Biosciences
A biotechnology company focused on revolutionizing industrial manufacturing of active pharmaceutical ingredients, like cannabinoids.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | CAD30.0m | Private Placement non VC |
| Total Funding | 000k | ||
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (99 %) | 118 % | 1230 % | 517 % | 43 % | 298 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (224 %) | (235508 %) | (135090 %) | (14713 %) | (1882 %) | (971 %) | (100 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (226 %) | (972221 %) | (339460 %) | (4617 %) | (1804 %) | (1112 %) | (133 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 910 % | 58280 % | 72570 % | 8655 % | 910 % | 580 % | 108 % |
Source: Company filings or news article
Related Content
Willow Biosciences operates in the biotechnology sector, specializing in the production of high-purity cannabinoids using synthetic biology. The company leverages advanced biotechnology to create pharmaceutical-grade CBD isolate, targeting industries such as pharmaceuticals, wellness, and cosmetics. Willow Biosciences serves clients who require high-quality, consistent, and sustainable cannabinoid products. The company operates on a B2B (business-to-business) model, generating revenue by supplying its cannabinoid isolates to manufacturers and distributors in various sectors. By utilizing synthetic biology, Willow Biosciences ensures a sustainable and scalable production process, reducing reliance on traditional cannabis cultivation. The company's innovative approach positions it as a leader in the cannabinoid production market, offering a reliable and eco-friendly alternative to traditional methods.
Keywords: biotechnology, synthetic biology, cannabinoids, CBD isolate, pharmaceutical-grade, sustainability, B2B, wellness, cosmetics, scalable production.